First thalidomide clinical trial in multiple myeloma: a decade. - Wikidata - awgldk - TriplyDB

First thalidomide clinical trial in multiple myeloma: a decade.

First thalidomide clinical trial in multiple myeloma: a decade.

http://www.wikidata.org/entity/Q36835212

about

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma What is the functional role of the thalidomide binding protein cereblon?Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.Immunomodulatory drugs in multiple myeloma.Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Genetic variations in multiple myeloma II: association with effect of treatment.Novel immunomodulatory compounds in multiple myeloma.In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.Predicting durable remissions following thalidomide therapy for relapsed myeloma.Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible.Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

P2860

Q24605861-A8A8A6E6-732B-402D-BF88-F041CB6F24F6 Q24635072-DDB2365A-0CD8-45CC-B221-4E40CDD0B4AD Q33628815-C4C62BE2-9A8B-47B9-95AB-98A44F28BA12 Q34325722-D7FC03DD-ECE6-418D-BE65-E15F01200C36 Q34485147-CA3EAD78-67B9-4527-8F7C-CED42BC216F2 Q35097319-391E8569-964F-4F12-8DD4-2D9A145FC971 Q35153760-F8F75730-19A3-4F9F-8F47-8D8C613CCD3C Q36612613-D226A325-47CB-4090-845C-CD6530ACEFDC Q37924890-DE800465-D155-4C50-8792-DDEF1A4F0C8E Q38069614-17AA0744-140E-44C0-912E-3A3710896A7B Q39425529-C1DB1B2D-7B82-4D6D-886A-75A6893F3BC9 Q44514465-91AC7A39-CA86-4FC8-9CD1-0A5D4C25038A Q44763325-C8176916-D528-4429-9D82-C009C2728FD2 Q47552538-627355E4-8EC5-4345-AFD0-16A3D415A77F Q56982314-FBA2B0CB-0751-4F22-A041-BE9A92A78F45

P2860

First thalidomide clinical trial in multiple myeloma: a decade.

http://www.wikidata.org/entity/Q36835212

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

First thalidomide clinical trial in multiple myeloma: a decade.

@en

type

label

First thalidomide clinical trial in multiple myeloma: a decade.

@en

prefLabel

First thalidomide clinical trial in multiple myeloma: a decade.

@en

P1433

Q36835212-CB5D0863-E97D-4597-8333-C84006CA104F

P1476

Q36835212-D1186D3E-7D89-43AE-A082-D1BCC8D45C10

P2093

Q36835212-1C50C27F-13AE-4F27-9ACF-6B7FAB371389

Q36835212-23F2E49F-6C5C-40EE-BA59-E3C0325F40FD

Q36835212-2F98F35E-21D8-43FD-A17E-EA37B5B3D429

Q36835212-543B9646-5CC5-4EB5-9743-7D1999AF9A5B

Q36835212-70988771-06C5-4E76-A8FE-C4610CBFEFDC

Q36835212-7B8093F9-8293-4E4C-9A01-C2CBAEB3B922

Q36835212-A977C506-D350-4FBC-A4A9-858BB8209376

Q36835212-E3D7A045-1A85-49A5-97EB-BC2443657525

Q36835212-F0F50CD9-C2B6-463F-B3B1-5EB400B4A438

P2860

Q36835212-0CE6EBA3-2DB8-4517-A359-187381CAC445

Q36835212-22597B96-25BC-4DBD-A551-22254C0EDDB6

Q36835212-33147830-A7D7-4534-9F25-B0366A97D405

Q36835212-45735CEA-6B4F-45D3-8EC4-5D5F2683022E

Q36835212-693FE135-3529-493C-8401-AD8AD48E7055

Q36835212-9E861EBC-0F0D-46DA-A8C8-5F8FEA94BB68

Q36835212-AAD61C47-C3C7-453D-A15A-11EBC508E194

Q36835212-AAD666DB-FAEB-441D-8FAE-F0D77E7A504C

Q36835212-B871BB6A-43B5-47C8-B710-30365C174CAD

Q36835212-C12017F3-C25B-41D4-988D-147E98009636

P304

Q36835212-DDB95FC5-074A-4AC1-B15F-54B47E69EDB1

P31

Q36835212-21D7194C-5E86-482A-BBAB-0743D1409174

P356

Q36835212-12DAC437-E1A8-4C10-B951-D95B3C7F1532

P407

Q36835212-3461D023-3D50-4065-998C-F1BC549B6EC5

P433

Q36835212-2EBD53A6-0DD0-47FD-ACF6-50B04EF76D1B

P478

Q36835212-0D2E8F46-3282-40D7-9ED3-AC138EB8EF2F

P50

Q36835212-0F81CB5B-50C3-4EAE-B168-624E325B3CD5

Q36835212-6853C260-50E0-499A-AED9-37E82E75CC22

Q36835212-6B30C930-9FB4-4561-9042-7B5B1A7A9942

Q36835212-93B3C128-A79A-4121-BC18-220E3DEBB4EF

P577

Q36835212-E1EE2184-F29C-41E2-8942-F122C42825AC

P5875

Q36835212-70F6C22F-F0E5-4DE5-BBD3-CD774AA42F23

P698

Q36835212-8435AAEA-5BC1-4ED4-8037-BF47113EE195

P921

Q36835212-D0DD7B82-6D6C-4BE4-BA37-3B3506572885

P932

Q36835212-F6EAEF66-2289-416F-AE76-163F76B93136

P356

BLOOD-2008-02-140954

P1433

P1476

First thalidomide clinical trial in multiple myeloma: a decade.

@en

P2093

Bonnie Jenkins

http://www.w3.org/2001/XMLSchema#string

David Siegel

http://www.w3.org/2001/XMLSchema#string

Jayesh Mehta

http://www.w3.org/2001/XMLSchema#string

Jerome Zeldis

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

John D Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Madhav Dhodapkar

http://www.w3.org/2001/XMLSchema#string

Seema Singhal

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Antitumor activity of thalidomide in refractory multiple myeloma.

The molecular classification of multiple myeloma

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Duration of survival in patients with myeloma treated with thalidomide.

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

P304

1035-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-02-140954

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5347121

http://www.w3.org/2001/XMLSchema#string

P698

18502827

http://www.w3.org/2001/XMLSchema#string

P921

P932

2515147

http://www.w3.org/2001/XMLSchema#string